Leishmaniasis Clinical Trial
Official title:
A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects
Verified date | February 2014 |
Source | IDRI |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prophylaxis of visceral leishmaniasis. The vaccine, identified as LEISH-F3 + GLA-SE, consists of the recombinant two-antigen Leishmania recombinant protein LEISH-F3 together with the adjuvant GLA-SE.
Status | Completed |
Enrollment | 36 |
Est. completion date | May 2013 |
Est. primary completion date | August 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: Subjects must meet ALL of the following criteria to be eligible for inclusion in the study: - Males and females 18 years to 45 years of age. - Must be in good general health as confirmed by a medical history and physical exam. - Female subjects of childbearing potential must have a negative serum pregnancy test at screening, a negative urine pregnancy test on the day of each study injection, must not be breast-feeding, and are required to use one of the following methods of contraception during the first 3 months of the study: hormonal (e.g. oral, transdermal, intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); abstinence; or bilateral tubal ligation (if no conception post-procedure). These precautions are necessary due to unknown effects that LEISH-F3 + GLA SE or LEISH-F3 alone might have in a fetus or newborn infant. - The following screening laboratory blood tests must have values within the normal ranges or not clinically significant as determined by the PI and Medical Monitor: sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, fasting glucose, fasting lipid panel, total WBC count, hemoglobin, and platelet count. - The following serology tests must be negative: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. - Negative urine test for recreational drugs and alcohol per Clinical Research Unit standards. - Urinalysis not clinically significant as determined by the study clinician. - Must be capable of completing a study diary in English. - Must give written informed consent, be able and willing to attend all evaluation visits, be reachable by telephone or personal contact by the study site personnel, and have a permanent address. Exclusion Criteria: Subjects who meet ANY of the following criteria will be excluded from the study (ineligible): - History of possible infection with Leishmania or previous exposure to Leishmania vaccines or experimental products containing GLA-SE. - Veterans who served in the military in the Middle East (Iran, Iraq), Afghanistan, or any other areas endemic to Leishmania. - Travelers to, or immigrants from, areas endemic to Leishmania. - Participation in another experimental protocol or receipt of any investigational products within the past 3 months. - Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy drugs or radiation) within the past 6 months. - Received a blood transfusion within the past 3 months. - Donated blood products (platelets, whole blood, plasma, etc.) within past 1 month. - Received any vaccine within past 1 month. Note: No immunizations while on study with the exception of seasonal influenza vaccine which should not be given until 1 month after the third study injection (Day 84). - History of autoimmune disease or other causes of immunosuppressive states. - History or evidence of any acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic, or renal disorders, controlled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine. - Rash, tattoos or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation. - BMI greater than 30 kg/m2 - Hypertension (systolic greater than 150 or diastolic greater than 95). - History of significant psychiatric illness with current use of medication. - Known or suspected alcohol or drug abuse within the past 6 months. - Chronic smoker (less than 20 pack years). - Subjects with a history of previous anaphylaxis or severe allergic reaction to vaccines, eggs, or unknown allergens. - Subjects who are unlikely to cooperate with the requirements of the study protocol. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Comprehensive Clinical Development NW, Inc. | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
IDRI |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients experiencing adverse events. | To evaluate the safety and tolerability of 20 µg of LEISH-F3 together with 2 or 5 µg of GLA-SE compared to 20 µg of LEISH-F3 alone following intramuscular administration on Days 0, 28, and 56. The safety assessments will be based on local and systemic reactions, including reported adverse events, changes in laboratory values, and changes in vital signs. The severity and relationship to treatment will be recorded for all adverse events. | 421 days | Yes |
Secondary | Immunogenicity | To assess the immunogenicity of LEISH-F3 + GLA-SE compared to LEISH-F3 alone by evaluating IgG antibody and T-cell responses to LEISH-F3 at specified timepoints. | Days 0, 7, 35, 63, 84, and 168. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT04504435 -
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
|
Phase 1 | |
Completed |
NCT00004755 -
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
|
Phase 2 | |
Completed |
NCT00657618 -
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
|
Phase 1/Phase 2 | |
Completed |
NCT04512742 -
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
|
N/A | |
Recruiting |
NCT00344188 -
Diagnosis and Treatment of Leishmania Infections
|
||
Active, not recruiting |
NCT03009422 -
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
|
N/A | |
Recruiting |
NCT05449717 -
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
|
||
Recruiting |
NCT06307171 -
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
|
N/A | |
Completed |
NCT01751048 -
LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
|
Phase 1 | |
Terminated |
NCT06124144 -
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
|
Phase 1 | |
Completed |
NCT00662012 -
Sodium Stibogluconate Treatment of Leishmaniasis
|
Phase 2 | |
Completed |
NCT03993093 -
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
|
||
Recruiting |
NCT03784248 -
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
|
||
Withdrawn |
NCT02429505 -
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
|
||
Completed |
NCT01377974 -
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
|
Phase 2 | |
Completed |
NCT02656797 -
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT01300975 -
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT00401349 -
Expression of Mif Alleles in Individuals With Leishmaniasis
|